PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $8,991,991 | -30.8% | 660,690 | 0.0% | 0.00% | -33.3% |
Q4 2021 | $12,996,000 | +22.9% | 660,690 | +100.6% | 0.00% | +50.0% |
Q3 2021 | $10,572,000 | -5.2% | 329,343 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $11,148,000 | -9.9% | 329,343 | 0.0% | 0.00% | -33.3% |
Q1 2021 | $12,370,000 | +13.1% | 329,343 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $10,941,000 | +15.0% | 329,343 | +27.0% | 0.00% | 0.0% |
Q3 2020 | $9,510,000 | +11.4% | 259,343 | 0.0% | 0.00% | +50.0% |
Q2 2020 | $8,535,000 | +27.5% | 259,343 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $6,696,000 | -32.2% | 259,343 | -18.3% | 0.00% | -33.3% |
Q4 2019 | $9,881,000 | – | 317,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |